Compumedics Targets FY26 Growth as It Builds on Global Neurodiagnostics Leadership

Compumedics Limited ( (AU:CMP) ) just unveiled an announcement.

Compumedics Limited, an Australian-headquartered medical technology group, develops and supplies diagnostic systems for sleep and neurological disorders, as well as ultrasonic brain blood flow monitoring equipment. With more than 25,000 systems installed globally and offices across key markets, the company serves hospitals, clinics, universities and research institutions through a predominantly B2B model.

The company reported A$31 million in revenue for the first half of FY26 and has issued full-year guidance of up to A$70 million in revenue and A$9 million in EBITDA, underscoring continued growth in its core markets. Compumedics holds leading market positions in sleep and neuro diagnostics in Australia and Japan, is a top supplier in China and Germany, and is strengthening its presence in the U.S., reinforcing its competitive standing in the global neurodiagnostics and sleep technology sector.

The most recent analyst rating on (AU:CMP) stock is a Sell with a A$0.29 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.

More about Compumedics Limited

Compumedics Limited, listed on the ASX under ticker CMP, is an Australia-based global medical technology company specializing in sleep and neurological disorder diagnostics and ultrasonic brain blood flow monitoring. Founded in 1987, the company operates with a team of about 180 employees across six countries, maintaining wholly owned offices in the U.S., Germany, France, Austria and Korea, and a network of more than 100 distributors worldwide.

Average Trading Volume: 79,824

Technical Sentiment Signal: Sell

Current Market Cap: A$56.93M

Learn more about CMP stock on TipRanks’ Stock Analysis page.